LTRN Stock Overview
A clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lantern Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$11.99 |
| 52 Week Low | US$3.04 |
| Beta | 1.57 |
| 11 Month Change | -10.47% |
| 3 Month Change | -30.63% |
| 1 Year Change | -22.61% |
| 33 Year Change | -64.27% |
| 5 Year Change | n/a |
| Change since IPO | -79.40% |
Recent News & Updates
Recent updates
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?
Nov 05
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Sep 02Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer
Jul 14Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth
May 20Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Feb 02We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Oct 13Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer
Aug 24Lantern Pharma: Drug Recycling With AI
Jun 08We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
May 05Lantern Pharma reports Q1 results
May 03Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like
Feb 19
Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma
Jan 04Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?
Dec 28Lantern: Early Stage 'Smart Drug' Discovery Company
Nov 25Shareholder Returns
| LTRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.0% | -10.5% | -2.1% |
| 1Y | -22.6% | 12.7% | 29.7% |
Return vs Industry: LTRN underperformed the US Biotechs industry which returned 12.7% over the past year.
Return vs Market: LTRN underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| LTRN volatility | |
|---|---|
| LTRN Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LTRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LTRN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 21 | Panna Sharma | www.lanternpharma.com |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation.
Lantern Pharma Inc. Fundamentals Summary
| LTRN fundamental statistics | |
|---|---|
| Market cap | US$34.02m |
| Earnings (TTM) | -US$19.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs LTRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LTRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.09m |
| Earnings | -US$19.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LTRN perform over the long term?
See historical performance and comparison